Lee Nguyen
Examiner (ID: 5319)
Most Active Art Unit | 2649 |
Art Unit(s) | 2649, 2683, 2611, 2618, 2647, 2745, 2746, 2682 |
Total Applications | 2249 |
Issued Applications | 1878 |
Pending Applications | 130 |
Abandoned Applications | 227 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18232067
[patent_doc_number] => 11596609
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-07
[patent_title] => Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/930369
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 76
[patent_figures_cnt] => 146
[patent_no_of_words] => 148720
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930369
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930369 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | Sep 6, 2022 | Issued |
Array
(
[id] => 17851903
[patent_doc_number] => 20220281945
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/750855
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17750855
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/750855 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | May 22, 2022 | Issued |
Array
(
[id] => 18018998
[patent_doc_number] => 20220370497
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/662766
[patent_app_country] => US
[patent_app_date] => 2022-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17662766
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/662766 | Compositions and methods for treating mesothelin positive cancers | May 9, 2022 | Issued |
Array
(
[id] => 18368129
[patent_doc_number] => 11648277
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-16
[patent_title] => Combination therapy with gold controlled transgenes
[patent_app_type] => utility
[patent_app_number] => 17/718095
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 42063
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17718095
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/718095 | Combination therapy with gold controlled transgenes | Apr 10, 2022 | Issued |
Array
(
[id] => 18215256
[patent_doc_number] => 11590169
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-02-28
[patent_title] => Compositions and methods for treating cancer with anti-CD123 immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/685132
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 37
[patent_no_of_words] => 35606
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685132
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/685132 | Compositions and methods for treating cancer with anti-CD123 immunotherapy | Mar 1, 2022 | Issued |
Array
(
[id] => 17681166
[patent_doc_number] => 11365407
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-21
[patent_title] => Methods for targeted insertion of DNA in genes
[patent_app_type] => utility
[patent_app_number] => 17/590613
[patent_app_country] => US
[patent_app_date] => 2022-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 15492
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590613
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/590613 | Methods for targeted insertion of DNA in genes | Jan 31, 2022 | Issued |
Array
(
[id] => 17625817
[patent_doc_number] => 20220160832
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/643410
[patent_app_country] => US
[patent_app_date] => 2021-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33144
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17643410
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/643410 | Binding proteins specific for RAS neoantigens and uses thereof | Dec 7, 2021 | Issued |
Array
(
[id] => 17641962
[patent_doc_number] => 20220169700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => GENE-EDITED NATURAL KILLER CELLS
[patent_app_type] => utility
[patent_app_number] => 17/538566
[patent_app_country] => US
[patent_app_date] => 2021-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17538566
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/538566 | Gene-edited natural killer cells | Nov 29, 2021 | Issued |
Array
(
[id] => 17904323
[patent_doc_number] => 11458156
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Compositions comprising circular polyribonucleotides and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/482346
[patent_app_country] => US
[patent_app_date] => 2021-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 64
[patent_no_of_words] => 53859
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17482346
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/482346 | Compositions comprising circular polyribonucleotides and uses thereof | Sep 21, 2021 | Issued |
Array
(
[id] => 17272952
[patent_doc_number] => 20210379150
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/408340
[patent_app_country] => US
[patent_app_date] => 2021-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17408340
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/408340 | Binding proteins specific for RAS neoantigens and uses thereof | Aug 19, 2021 | Issued |
Array
(
[id] => 17421485
[patent_doc_number] => 11254930
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-22
[patent_title] => Methods for targeted insertion of DNA in genes
[patent_app_type] => utility
[patent_app_number] => 17/366290
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 15456
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366290
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/366290 | Methods for targeted insertion of DNA in genes | Jul 1, 2021 | Issued |
Array
(
[id] => 17938417
[patent_doc_number] => 11472858
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
[patent_app_type] => utility
[patent_app_number] => 17/352915
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 9805
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/352915 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Jun 20, 2021 | Issued |
Array
(
[id] => 17938417
[patent_doc_number] => 11472858
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
[patent_app_type] => utility
[patent_app_number] => 17/352915
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 9805
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/352915 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Jun 20, 2021 | Issued |
Array
(
[id] => 17938417
[patent_doc_number] => 11472858
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
[patent_app_type] => utility
[patent_app_number] => 17/352915
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 9805
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/352915 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Jun 20, 2021 | Issued |
Array
(
[id] => 17938417
[patent_doc_number] => 11472858
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
[patent_app_type] => utility
[patent_app_number] => 17/352915
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 9805
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/352915 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | Jun 20, 2021 | Issued |
Array
(
[id] => 17618896
[patent_doc_number] => 11337922
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-24
[patent_title] => Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell
[patent_app_type] => utility
[patent_app_number] => 17/330342
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 24869
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330342
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330342 | Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell | May 24, 2021 | Issued |
Array
(
[id] => 17192092
[patent_doc_number] => 11160822
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-02
[patent_title] => Compositions comprising circular polyribonucleotides and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/313963
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 64
[patent_no_of_words] => 53833
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313963
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313963 | Compositions comprising circular polyribonucleotides and uses thereof | May 5, 2021 | Issued |
Array
(
[id] => 17052521
[patent_doc_number] => 20210261955
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/214461
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 101588
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214461
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/214461 | Compositions and methods for treating hemoglobinopathies | Mar 25, 2021 | Issued |
Array
(
[id] => 17193333
[patent_doc_number] => 11162076
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-02
[patent_title] => Methods and compositions for inducing hematopoietic cell differentiation
[patent_app_type] => utility
[patent_app_number] => 17/199301
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 71
[patent_no_of_words] => 53309
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 171
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17199301
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/199301 | Methods and compositions for inducing hematopoietic cell differentiation | Mar 10, 2021 | Issued |
Array
(
[id] => 17767610
[patent_doc_number] => 11399522
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-02
[patent_title] => Animal models and therapeutic molecules
[patent_app_type] => utility
[patent_app_number] => 17/180258
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 49490
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 406
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180258
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180258 | Animal models and therapeutic molecules | Feb 18, 2021 | Issued |